Tirzepatide : Targets both GIP and GLP-1 receptors, potentially offering broader metabolic benefits
The current understanding points to a potential biphasic pattern in GLP-1 RA studies, where any observed early worsening may be related to rapid glycemic improvement rather than direct retinal toxicity, particularly in patients with pre-existing retinopathy, poor glycemic control, and those undergoing HbA1c reduction 47
Semaglutide may be used by individuals with liver conditions, but it requires careful monitoring and possibly a modified treatment plan
Current active state licensing should be verified directly with Boothwyn or through the relevant state board before placing any prescription
If needed, a more precise test can be done
Metabolic Game-Changer : It improves blood sugar control, reduces liver glucose production, and supports cardiovascular and liver health